Exon 7 splicing variant of estrogen receptor α is associated with pathological invasiveness in smoking‑independent lung adenocarcinoma

Suzuki,Ayumi; Okuda,Katsuhiro; Yano,Motoki; Oda,Risa; Sakane,Tadashi; Kawano,Osamu; Haneda,Hiroshi; Moriyama,Satoru; Nakanishi,Makoto; Nakanishi,Ryoichi

doi:10.3892/ol.2017.6216

Exon 7 splicing variant of estrogen receptor α is associated with pathological invasiveness in smoking‑independent lung adenocarcinoma

Authors:
- Ayumi Suzuki
- Katsuhiro Okuda
- Motoki Yano
- Risa Oda
- Tadashi Sakane
- Osamu Kawano
- Hiroshi Haneda
- Satoru Moriyama
- Makoto Nakanishi
- Ryoichi Nakanishi
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho, Nagoya 467‑8601, Japan, Division of Cancer Cell Biology, Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo, Minato, Tokyo 108‑8639, Japan
Published online on: May 19, 2017 https://doi.org/10.3892/ol.2017.6216
Pages: 891-898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with smoking-independent lung cancer mainly consist of females, yet the molecular background of this epidemiological feature, other than epidermal growth factor receptor (EGFR) mutation, remains unclear. Several studies have revealed the association between female hormone‑associated factors and the prognosis of lung cancer, however the data remain inconsistent. The present study focused on the expression of estrogen receptor (ER)α in order to elucidate this association in smoking‑independent lung cancer. Immunohistochemistry staining (IHC) of aromatase, ERα and ERβ was performed against formalin‑treated tissues from 38 patients who had never‑smoked who underwent complete surgical resection between 2012 and 2013. Among them, adequate RNA of the tumor and adjacent normal lung cancer was extracted from 31 matching deep frozen samples. Considering the IHC results, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to measure the expression level of 2 different exons of ERα, exon 6 and exon 7, which are part of the ligand binding domain of ERα, using the Taqman gene expression assay. Extra‑nuclear expression of ERα using IHC demonstrated a statistically significant association with pathological invasiveness. RT‑qPCR results exhibited a decreased expression of ERα exon 7 in invasive tumor tissues, compared with their adjacent normal tissues. This is consistent with the findings of previous in vitro studies indicating that extra‑nuclear ERα were exon 7 splicing variants. No difference was observed in ERα exon 7 expression between normal and tumor tissues in non‑invasive lung cancer tissues. When considering the EGFR mutation status, EGFR wild‑type lung cancers exhibited decreased ERα exon 7 expression levels compared with EGFR mutated lung cancers. Extra‑nuclear expression of ERα, which may represent exon 7 splicing variants of ERα, showed statistical association with pathological invasiveness in smoking‑independent lung cancer. The post‑translational splicing mechanism of ERα may be involved in the acquired invasiveness of smoking independent lung cancer.

View Figures

View References

1	World Cancer Reports 2014. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014September 27–2016
2	U.S. National Cancer Institute and World Health Organization, . The Economics of Tobacco and Tobacco Control. National Cancer Institute Tobacco Control Monograph 21. NIH Publication No. 16-CA-8029A. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Bethesda, MD: World Health Organization, Geneva; 2016
3	Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, Kouso H, Kometani T, Shoji F and Maehara Y: Never-smoking nonsmall cell lung cancer as a separate entity: Clinicopathologic features and survival. Cancer. 113:1012–1018. 2008. View Article : Google Scholar : PubMed/NCBI
4	Subramanian J and Govindan R: Lung cancer in never smokers: A review. J Clin Oncol. 25:561–570. 2007. View Article : Google Scholar : PubMed/NCBI
5	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T: Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl Lung Cancer Res. 3:205–211. 2014.PubMed/NCBI
7	Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K and Buerger H: Mechanisms of egfr gene transcription modulation: Relationship to cancer risk and therapy response. Clin Cancer Res. 12:7252–7260. 2006. View Article : Google Scholar : PubMed/NCBI
8	Kohno M, Okamoto T, Suda K, Shimokawa M, Kitahara H, Shimamatsu S, Konishi H, Yoshida T, Takenoyama M, Yano T and Maehara Y: Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. Clin Cancer Res. 20:3613–3622. 2014. View Article : Google Scholar : PubMed/NCBI
9	Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, et al: Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 8:270–278. 2013. View Article : Google Scholar : PubMed/NCBI
10	Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T and Sasano H: Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 14:4417–4426. 2008. View Article : Google Scholar : PubMed/NCBI
11	Shimizu K, Hirami Y, Saisho S, Yukawa T, Maeda A, Yasuda K and Nakata M: Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients. World J Surg Oncol. 10:1412012. View Article : Google Scholar : PubMed/NCBI
12	Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, et al: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 15:5359–5368. 2009. View Article : Google Scholar : PubMed/NCBI
13	Rouquette I, Lauwers-Cances V, Allera C, Brouchet L, Milia J, Nicaise Y, Laurent J, Delisle MB, Favre G, Didier A and Mazières J: Characteristics of lung cancer in women: Importance of hormonal and growth factors. Lung Cancer. 76:280–285. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wang Z, Li Z, Ding X, Shen Z, Liu Z, An T, Duan J, Zhong J, Wu M, Zhao J, et al: ERbeta localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Sci Rep. 5:113922015. View Article : Google Scholar : PubMed/NCBI
15	Verma MK, Miki Y, Abe K, Nagasaki S, Niikawa H, Suzuki S, Kondo T and Sasano H: Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome. Life Sci. 91:800–808. 2012. View Article : Google Scholar : PubMed/NCBI
16	Mah V, Marquez D, Alavi M, Maresh EL, Zhang L, Yoon N, Horvath S, Bagryanova L, Fishbein MC, Chia D, et al: Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer. 74:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nose N, Uramoto H, Iwata T, Hanagiri T and Yasumoto K: Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer. 71:350–355. 2011. View Article : Google Scholar : PubMed/NCBI
18	Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S, et al: Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol. 41:190–198. 2010. View Article : Google Scholar : PubMed/NCBI
19	Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, Onitsuka T and Yasumoto K: Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 27:411–417. 2009. View Article : Google Scholar : PubMed/NCBI
20	Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, et al: Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun. 285:340–347. 2001. View Article : Google Scholar : PubMed/NCBI
21	Tanaka K, Shimizu K, Kakegawa S, Ohtaki Y, Nagashima T, Kaira K, Horiguchi J, Oyama T and Takeyoshi I: Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. Am J Transl Res. 8:81–97. 2016.PubMed/NCBI
22	Schwartz AG, Ray RM, Cote ML, Abrams J, Sokol RJ, Hendrix SL, Chen C, Chlebowski RT, Hubbell FA, Kooperberg C, et al: Hormone use, reproductive history, and risk of lung cancer: The women's health initiative studies. J Thorac Oncol. 10:1004–1013. 2015. View Article : Google Scholar : PubMed/NCBI
23	Mazieres J, Rouquette I, Lepage B, Milia J, Brouchet L, Guibert N, Beau-Faller M, Validire P, Hofman P and Fouret P: Specificities of lung adenocarcinoma in women who have never smoked. J Thorac Oncol. 8:923–929. 2013. View Article : Google Scholar : PubMed/NCBI
24	International Union Against Cancer (UICC), . TNM Classification of Malignant Tumours. Sobin LH, Gospodarowicz MK and Wittekind C: 7th. Wiley-Blackwell; Oxford: 2009
25	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, van Schil PE, et al: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Ivanova MM, Mazhawidza W, Dougherty SM and Klinge CM: Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am J Respir Cell Mol Biol. 42:320–330. 2010. View Article : Google Scholar : PubMed/NCBI
28	Fasco MJ, Hurteau GJ and Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol. 188:125–140. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y and Ogawa J: Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 11:5084–5089. 2005. View Article : Google Scholar : PubMed/NCBI
30	Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J and Brooks S: Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
31	Márquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 72:135–143. 2007. View Article : Google Scholar : PubMed/NCBI
32	Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR and Siegfried JM: Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 17:154–164. 2011. View Article : Google Scholar : PubMed/NCBI
33	Sun HB, Zheng Y, Ou W, Fang Q, Li P, Ye X, Zhang BB, Yang H and Wang SY: Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. Ann Thorac Surg. 91:1562–1567. 2011. View Article : Google Scholar : PubMed/NCBI
34	Hirschfeld M, Ouyang YQ, Jaeger M, Erbes T, Orlowska-Volk M, Zur Hausen A and Stickeler E: HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer. BMC Cancer. 15:862015. View Article : Google Scholar : PubMed/NCBI
35	Chen M and Manley JL: Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. Nat Rev Mol Cell Biol. 10:741–754. 2009.PubMed/NCBI